Twist Bioscience Corp (TWST) Stock Analysis and Metrics

Twist Bioscience

NASDAQ: TWST

$90.35 ▼ -0.29 (-0.31%)

At close: Jul 13, 2026 · 4:00 PM UTC

Financial Ratios

Market Cap6.31 Bn

P/E-77.63

P/S15.41

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)15.00 Mn

Revenue Growth (1y) (Qtr)19.31

Add ratio to table…

About

Twist Bioscience Corporation develops a proprietary DNA synthesis platform that enables the production of synthetic genes oligonucleotides and related biologics for research and industrial applications. The company miniaturizes chemical DNA synthesis reactions onto a silicon chip allowing the parallel manufacture of up to one million oligonucleotides per chip. This technology reduces reagent consumption and cost while increasing speed and scalability compared with traditional plate based methods. Twist Bioscience serves markets in health care chemicals materials food agriculture and academic research by providing products that support drug discovery enzyme engineering crop improvement and basic biological investigation.

The company generates revenue primarily from the sale of synthetic biology products next generation sequencing tools and biopharma services. Synthetic biology revenue comes from clonal and non clonal genes gene fragments oligonucleotide pools and immunoglobulin G protein products. Next generation sequencing revenue is derived from target enrichment probes library preparation kits synthetic controls and related workflow solutions. Biopharma services revenue is earned through antibody discovery partnership programs library generation screening developability assays and antibody expression and characterization activities. In fiscal year 2025 the company served more than 3 800 customers and reported total revenue of 376.6 million dollars. Revenue by sector included 215.1 million dollars from health care 93.2 million dollars from chemicals materials 65.9 million dollars from academic research and 2.4 million dollars from food agriculture.

The company operates through the following segments Synthetic Biology Next Generation Sequencing Tools and Biopharma Services.

• The Synthetic Biology segment designs manufactures and sells clonal genes non clonal genes gene fragments oligonucleotide pools and immunoglobulin G proteins. Products are delivered through standard and express timelines with the express option providing delivery within five business days at a premium price. The segment serves biotech pharma industrial chemical agricultural companies and academic laboratories for applications such as drug discovery enzyme engineering crop trait improvement and basic research.

• The Next Generation Sequencing Tools segment produces target enrichment probes library preparation kits synthetic controls and RNA sequencing workflows. These products improve sequencing accuracy lower downstream costs and enable rapid sample to sequencer workflows for applications such as liquid biopsy minimal residual disease and cancer diagnostics. Customers include diagnostic companies hospitals research institutions agricultural biotech firms and consumer genetics companies.

• The Biopharma Services segment provides antibody discovery and optimization services under partnership agreements with pharmaceutical and biotechnology companies. Services encompass library generation high throughput screening developability assays antibody expression and characterization and lead selection. Revenue is generated via licensing fees fee for service arrangements and success based milestones tied to clinical regulatory and commercial outcomes.

Twist Bioscience holds a strong position in the synthetic biology market due to its silicon based DNA synthesis platform that delivers high throughput low cost and rapid turnaround. The company competes with established nucleic acid providers such as GenScript Integrated DNA Technologies Thermo Fisher Scientific and Eurofins Genomics as well as newer entrants like Ansa Biotechnologies and Telesis Bio. In the next generation sequencing space Twist faces competition from Illumina Roche Agilent and other suppliers of library preparation and target enrichment products. Its competitive advantages include proprietary silicon chip technology a fully integrated software and automation platform and a broad product portfolio that spans genes oligonucleotides proteins and antibody services. The company’s ability to scale production while maintaining low error rates and short lead times enables it to win market share from legacy providers that rely on multi well plate processes.

Twist Bioscience serves a global customer base of more than 3 800 organizations spanning health care chemicals materials food agriculture and academic research. Specific partners include Bayer Boehringer Ingelheim GmbH Takeda Pharmaceutical Company Limited Adicet Bio Ono Pharmaceutical Ltd Kyowa Kirin Invetx Inc Astellas Pharma Inc and Neogene Therapeutics Inc. The company also works with academic laboratories government agencies and contract research organizations that use its products for enzyme engineering vaccine development and sustainable chemical production.

Investment Thesis

▲ Bull case

Twist Bioscience has established a durable competitive moat through its proprietary silicon-based DNA synthesis platform and vertical integration initiatives, which are now yielding tangible financial benefits. The company's achievement of 53.4% gross margin in Q3 FY25—up over 10 percentage points year-over-year—reflects more than just favorable product mix; it demonstrates the scalability of its manufacturing processes and cost discipline. This is further reinforced by SynBio contribution margins approaching NGS levels, with 75%-80% of incremental revenue now dropping to gross margin, a direct result of operational enhancements like the internal primer manufacturing process developed in under 12 months with under $3 million investment. This initiative not only strengthens supply chain resilience but also unlocks expansion in the large gene fragments market by eliminating external dependency on primer suppliers, reducing turnaround times, and enhancing customer flexibility. Such improvements position Twist to capture share in high-growth adjacent markets while maintaining pricing power, a factor the market may be underestimating as it focuses on sequential NGS volatility rather than the structural margin expansion underway. The company's ability to drive gross margin improvement while simultaneously investing in innovation—evidenced by new product launches like Complex Genes and Express Genes—signals a shift from cost-cutting to value-creating growth, with gross margin expansion now serving as a foundation for top-line acceleration rather than a trade-off.
Twist Bioscience is strategically positioned to capitalize on the accelerating convergence of AI-driven drug discovery and synthetic biology, a catalyst that remains underappreciated in current guidance. The recent collaboration with LenioBio to integrate its ALiCE® cell-free protein expression platform with Twist’s DNA manufacturing creates a closed-loop "lab-in-the-wheel" system that accelerates design-build-test cycles for AI-generated proteins and antibodies—directly addressing a critical bottleneck in biologics R&D where computational designs often fail in wet-lab validation due to manufacturability issues. This integration enables rapid iteration with biology-native data, improving AI model accuracy and reducing development timelines, which is particularly valuable in nucleic acid therapeutics and monoclonal antibody discovery. Management has explicitly highlighted AI as a growth catalyst, noting that demand for complex, manufacturable sequences is rising as researchers require exact replication of AI-generated designs without sequence alteration. The launch of Complex Genes—capable of synthesizing sequences up to 7,000 base pairs with 99.5% reliability for clonal genes and 99.9% for all DNA products—directly serves this need by enabling one-stop-shop access for challenging constructs essential in cell/gene therapies, mRNA therapeutics, and AI-guided protein design. With AI-driven drug discovery expanding exponentially and Twist’s platform uniquely equipped to bridge the digital-to-wet-lab gap, the company is poised to benefit from sustained, high-margin demand that extends beyond traditional NGS and SynBio use cases, creating a structural tailwind the market has not fully priced into its growth outlook.
Twist Bioscience’s geographic diversification and resilient customer base are providing underrecognized insulation against regional headwinds, particularly in APAC and EMEA, while enabling sequential growth across all quarters despite macroeconomic uncertainty. Although APAC revenue declined slightly to $5.9 million from $6.5 million year-over-year, with China representing only 1.5% of total revenue, the company’s EMEA segment grew 30% year-over-year to $30.7 million, driven by strong demand from pharma, biotech, and diagnostics customers unaffected by tariff concerns. This regional shift reflects successful navigation of trade volatility through Twist’s low-variable-cost, high-speed DNA offerings, which allow customers to achieve more experiments per budget dollar—a compelling value proposition during funding constraints. Furthermore, the Americas segment grew 16% to $59.4 million, and the addition of hundreds of net new SynBio customers, coupled with 608 NGS served and 155 adopting new products quarter-over-quarter, underscores broadening commercial traction beyond legacy accounts. Management’s emphasis on penetrating the "long tail" of academic and government markets through products like FlexPrep for AgBio and expanded characterization tools indicates a deliberate strategy to reduce reliance on large, lumpy contracts while building sticky, recurring revenue streams. This diversified, multi-vertical customer base—spanning diagnostics, therapeutics, industrial, agriculture, and research—creates a recession-resilient growth engine that supports continued sequential expansion, a factor the market may be overlooking amid near-term NGS normalization fears tied to a single top-10 customer transition.

Twist Bioscience has established a durable competitive moat through its proprietary silicon-based DNA synthesis platform and vertical integration initiatives, which are now yielding tangible financial benefits. The company's achievement of 53.4% gross margin in Q3 FY25—up over 10 percentage points year-over-year—reflects more than just favorable product mix; it demonstrates the scalability of its manufacturing processes and cost discipline. This is further reinforced by SynBio contribution margins approaching NGS levels, with 75%-80% of incremental revenue now dropping to gross margin, a direct result of operational enhancements like the internal primer manufacturing process developed in under 12 months with under $3 million investment. This initiative not only strengthens supply chain resilience but also unlocks expansion in the large gene fragments market by eliminating external dependency on primer suppliers, reducing turnaround times, and enhancing customer flexibility. Such improvements position Twist to capture share in high-growth adjacent markets while maintaining pricing power, a factor the market may be underestimating as it focuses on sequential NGS volatility rather than the structural margin expansion underway. The company's ability to drive gross margin improvement while simultaneously investing in innovation—evidenced by new product launches like Complex Genes and Express Genes—signals a shift from cost-cutting to value-creating growth, with gross margin expansion now serving as a foundation for top-line acceleration rather than a trade-off.
Twist Bioscience is strategically positioned to capitalize on the accelerating convergence of AI-driven drug discovery and synthetic biology, a catalyst that remains underappreciated in current guidance. The recent collaboration with LenioBio to integrate its ALiCE® cell-free protein expression platform with Twist’s DNA manufacturing creates a closed-loop "lab-in-the-wheel" system that accelerates design-build-test cycles for AI-generated proteins and antibodies—directly addressing a critical bottleneck in biologics R&D where computational designs often fail in wet-lab validation due to manufacturability issues. This integration enables rapid iteration with biology-native data, improving AI model accuracy and reducing development timelines, which is particularly valuable in nucleic acid therapeutics and monoclonal antibody discovery. Management has explicitly highlighted AI as a growth catalyst, noting that demand for complex, manufacturable sequences is rising as researchers require exact replication of AI-generated designs without sequence alteration. The launch of Complex Genes—capable of synthesizing sequences up to 7,000 base pairs with 99.5% reliability for clonal genes and 99.9% for all DNA products—directly serves this need by enabling one-stop-shop access for challenging constructs essential in cell/gene therapies, mRNA therapeutics, and AI-guided protein design. With AI-driven drug discovery expanding exponentially and Twist’s platform uniquely equipped to bridge the digital-to-wet-lab gap, the company is poised to benefit from sustained, high-margin demand that extends beyond traditional NGS and SynBio use cases, creating a structural tailwind the market has not fully priced into its growth outlook.
Twist Bioscience’s geographic diversification and resilient customer base are providing underrecognized insulation against regional headwinds, particularly in APAC and EMEA, while enabling sequential growth across all quarters despite macroeconomic uncertainty. Although APAC revenue declined slightly to $5.9 million from $6.5 million year-over-year, with China representing only 1.5% of total revenue, the company’s EMEA segment grew 30% year-over-year to $30.7 million, driven by strong demand from pharma, biotech, and diagnostics customers unaffected by tariff concerns. This regional shift reflects successful navigation of trade volatility through Twist’s low-variable-cost, high-speed DNA offerings, which allow customers to achieve more experiments per budget dollar—a compelling value proposition during funding constraints. Furthermore, the Americas segment grew 16% to $59.4 million, and the addition of hundreds of net new SynBio customers, coupled with 608 NGS served and 155 adopting new products quarter-over-quarter, underscores broadening commercial traction beyond legacy accounts. Management’s emphasis on penetrating the "long tail" of academic and government markets through products like FlexPrep for AgBio and expanded characterization tools indicates a deliberate strategy to reduce reliance on large, lumpy contracts while building sticky, recurring revenue streams. This diversified, multi-vertical customer base—spanning diagnostics, therapeutics, industrial, agriculture, and research—creates a recession-resilient growth engine that supports continued sequential expansion, a factor the market may be overlooking amid near-term NGS normalization fears tied to a single top-10 customer transition.

▼ Bear case

Twist Bioscience remains heavily reliant on the execution and adoption timelines of a limited number of large NGS customers, creating significant near-term revenue volatility that the market may be underestimating despite management’s attempts to frame it as temporary. The company explicitly guided for a planned $5 million revenue normalization in Q4 FY25 due to a top 10 NGS account transitioning from validation to commercial deployment, with additional impact expected in Q1 FY26—a situation that directly contradicts the narrative of continued sequential growth across all business segments. While leadership characterizes this as a "critical inflection point" unlocking multiyear opportunities, the near-term step-down introduces modeling uncertainty and execution risk, particularly if the customer’s rollout encounters delays or scalability issues in clinical diagnostics. Furthermore, historical dependence on non-recurring large contracts is evident in both SynBio and Industrial Chemical segments: Emily Leproust acknowledged a "tough comp" in SynBio due to a non-repeating big contract, and Industrial Chemical revenue remained flat year-over-year solely because of the absence of a one-time order from the prior year. This pattern suggests that underlying organic growth, while improving, may not be as robust as headline figures imply, and the company’s ability to consistently replace such large, lumpy revenue with predictable, recurring streams remains unproven. The market may be overindexing on the long-term potential of these transitions while underpricing the near-term cash flow volatility and potential disappointment if commercialization timelines slip.
Twist Bioscience’s path to adjusted EBITDA breakeven remains contingent on sustained revenue growth and OpEx control, yet emerging cost pressures and investment priorities could undermine margin expansion efforts despite recent gross margin gains. Although the company expects to realize approximately $5 million per quarter in OpEx savings from the Atlas transaction starting in Q4 FY25, leadership has indicated plans to reinvest these savings—and additional capital—into product innovation and portfolio expansion, with Adam Laponis stating that OpEx investments will be "modest" but focused on accelerating growth where opportunities arise. This reinvestment strategy, while necessary for long-term competitiveness, risks delaying profitability if revenue growth fails to keep pace with increased spending, particularly given that adjusted EBITDA was still an $8 million loss in Q3 FY25 despite the Atlas gain. Furthermore, the company’s guidance for FY25 adjusted EBITDA loss of $45–$47 million implies only a $14 million improvement from the prior year’s loss, suggesting that breakeven may not be achieved until well into FY26—or later—if growth decelerates or OpEx creeps upward. The market may be overly optimistic about the timing of profitability, especially as management shifts focus from gross margin expansion to top-line acceleration, potentially reigniting cost discipline concerns if revenue growth does not materialize as expected amid macroeconomic headwinds or competitive pressures in NGS and SynBio.
Twist Bioscience’s expansion into adjacent markets like AgBio and AI-enabled protein expression, while strategically sound, carries significant execution risk and uncertain monetization timelines that the market may be overlooking in favor of narrative-driven optimism. The FlexPrep launch targeting AgBio and the LenioBio collaboration for cell-free protein expression represent ambitious bets on diversifying beyond clinical NGS, yet both initiatives face hurdles: AgBio remains a fragmented, price-sensitive market with entrenched competition from established players, and the success of the LenioBio partnership depends on widespread adoption of AI-driven protein design workflows—which, despite hype, are still nascent and unproven at scale in drug development. Moreover, the company’s investment in complex gene synthesis (Complex Genes) and extended manufacturing capabilities requires sustained R&D and commercialization effort, with revenue contribution likely lagging by 12–24 months as seen with prior product launches like Express Genes. While Emily Leproust cites AI as a "great catalyst," the conversion of AI-generated designs into reliable, manufacturable DNA sequences remains a technical challenge, and Twist’s ability to capture value from this trend depends on not only technological leadership but also pricing power in a market where alternatives—including in-house synthesis and competing synthetic biology providers—are rapidly evolving. The market may be prematurely pricing in high-margin, recurring revenue from these frontier initiatives without sufficient evidence of customer traction, pricing sustainability, or scalable go-to-market execution, creating a valuation gap between narrative and near-term financial reality.

Twist Bioscience remains heavily reliant on the execution and adoption timelines of a limited number of large NGS customers, creating significant near-term revenue volatility that the market may be underestimating despite management’s attempts to frame it as temporary. The company explicitly guided for a planned $5 million revenue normalization in Q4 FY25 due to a top 10 NGS account transitioning from validation to commercial deployment, with additional impact expected in Q1 FY26—a situation that directly contradicts the narrative of continued sequential growth across all business segments. While leadership characterizes this as a "critical inflection point" unlocking multiyear opportunities, the near-term step-down introduces modeling uncertainty and execution risk, particularly if the customer’s rollout encounters delays or scalability issues in clinical diagnostics. Furthermore, historical dependence on non-recurring large contracts is evident in both SynBio and Industrial Chemical segments: Emily Leproust acknowledged a "tough comp" in SynBio due to a non-repeating big contract, and Industrial Chemical revenue remained flat year-over-year solely because of the absence of a one-time order from the prior year. This pattern suggests that underlying organic growth, while improving, may not be as robust as headline figures imply, and the company’s ability to consistently replace such large, lumpy revenue with predictable, recurring streams remains unproven. The market may be overindexing on the long-term potential of these transitions while underpricing the near-term cash flow volatility and potential disappointment if commercialization timelines slip.
Twist Bioscience’s path to adjusted EBITDA breakeven remains contingent on sustained revenue growth and OpEx control, yet emerging cost pressures and investment priorities could undermine margin expansion efforts despite recent gross margin gains. Although the company expects to realize approximately $5 million per quarter in OpEx savings from the Atlas transaction starting in Q4 FY25, leadership has indicated plans to reinvest these savings—and additional capital—into product innovation and portfolio expansion, with Adam Laponis stating that OpEx investments will be "modest" but focused on accelerating growth where opportunities arise. This reinvestment strategy, while necessary for long-term competitiveness, risks delaying profitability if revenue growth fails to keep pace with increased spending, particularly given that adjusted EBITDA was still an $8 million loss in Q3 FY25 despite the Atlas gain. Furthermore, the company’s guidance for FY25 adjusted EBITDA loss of $45–$47 million implies only a $14 million improvement from the prior year’s loss, suggesting that breakeven may not be achieved until well into FY26—or later—if growth decelerates or OpEx creeps upward. The market may be overly optimistic about the timing of profitability, especially as management shifts focus from gross margin expansion to top-line acceleration, potentially reigniting cost discipline concerns if revenue growth does not materialize as expected amid macroeconomic headwinds or competitive pressures in NGS and SynBio.
Twist Bioscience’s expansion into adjacent markets like AgBio and AI-enabled protein expression, while strategically sound, carries significant execution risk and uncertain monetization timelines that the market may be overlooking in favor of narrative-driven optimism. The FlexPrep launch targeting AgBio and the LenioBio collaboration for cell-free protein expression represent ambitious bets on diversifying beyond clinical NGS, yet both initiatives face hurdles: AgBio remains a fragmented, price-sensitive market with entrenched competition from established players, and the success of the LenioBio partnership depends on widespread adoption of AI-driven protein design workflows—which, despite hype, are still nascent and unproven at scale in drug development. Moreover, the company’s investment in complex gene synthesis (Complex Genes) and extended manufacturing capabilities requires sustained R&D and commercialization effort, with revenue contribution likely lagging by 12–24 months as seen with prior product launches like Express Genes. While Emily Leproust cites AI as a "great catalyst," the conversion of AI-generated designs into reliable, manufacturable DNA sequences remains a technical challenge, and Twist’s ability to capture value from this trend depends on not only technological leadership but also pricing power in a market where alternatives—including in-house synthesis and competing synthetic biology providers—are rapidly evolving. The market may be prematurely pricing in high-margin, recurring revenue from these frontier initiatives without sufficient evidence of customer traction, pricing sustainability, or scalable go-to-market execution, creating a valuation gap between narrative and near-term financial reality.

Information by industry sector. Breakdown of Revenue (2025)

Peer Comparison

Companies in the Diagnostics & Research

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	WAT	Waters Corp /De/	31,055.11 Bn	69,126.88	8,236.16	4.86 Bn
2	TMO	Thermo Fisher Scientific Inc.	191.02 Bn	27.63	4.23	43.16 Bn
3	DHR	Danaher Corp /De/	137.16 Bn	37.32	5.54	18.48 Bn
4	IDXX	Idexx Laboratories Inc /De	42.82 Bn	39.09	9.63	0.83 Bn
5	NTRA	Natera, Inc.	39.09 Bn	-172.71	15.63	0.02 Bn
6	A	Agilent Technologies, Inc.	37.61 Bn	26.60	5.20	0.30 Bn
7	IQV	Iqvia Holdings Inc.	34.23 Bn	35.84	2.06	15.83 Bn
8	ILMN	Illumina, Inc.	28.14 Bn	32.98	6.40	1.49 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Information by industry sector. Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Information by industry sector. Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password